To aid in the research and development of rapid cancer tests, Evolution committed to a three-year partnership with the University of Queensland (UQ) in 2019. Researchers from UQ developed a breakthrough novel Immuno-Storm chip technology, using gold nanoparticles that can rapidly detect cancer cells in the human body with the potential to enable early diagnosis for all cancer types and improve survival rates up to 98%. It is considered a disruptive technology, and Evolution’s support assists in commercialising it, generating intellectual property, and contributing to the growth of our Biotechnology industry.
We are exploring opportunities to continue our support, with research expanded to include long-term COVID-19 immune response. Following the successful initial clinical demonstration and advancement of the technology and research, Professor Trau, Director of the Centre for Personalised Medicine at UQ’s Australian Institute for Bioengineering and Nanotechnology, and the UQ scientists who pioneered the technology, are focused on critical research in the application of the Immuno-Storm chip technology to long-term COVID-19 immune response.
This innovative research offers an opportunity for Evolution to improve the health of people in our communities and globally, save lives, build the diversity of new gold-based products in medical diagnostics, and demonstrate the relevance of gold.